ArticleFrontiers in endocrinology2026
Comparison of ultrasound-guided percutaneous radiofrequency ablation and reoperation for nerve-adjacent cervical lymph node recurrence of papillary thyroid carcinoma: a propensity score-matched study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Safety and Efficacy of Thermal Ablation for Cervical Lymph Node Metastasis from Papillary Thyroid Carcinoma: A Systematic Review of Available Evidence.Medical sciences (Basel, Switzerland) · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To compare the short-term efficacy and safety of ultrasound-guided percutaneous radiofrequency ablation (RFA) and reoperation (RO) for recurrent papillary thyroid carcinoma presenting as solitary cervical lymph node metastasis (R-PTC-SCLNM) located in perineural regions (PNRs). Methods: This retrospective study included patients with R-PTC-SCLNM in PNRs who underwent RFA or RO. Propensity score matching was performed to balance baseline characteristics. Kaplan-Meier analysis was used to assess recurrence-free survival, and treatment outcomes and complications were compared between groups. Subgroup analyses were conducted according to the anatomical relationship between metastatic lymph nodes and adjacent nerves. Results: After PSM, 71 matched pairs were included. In the RFA group, the mean volume reduction ratio (VRR) at 24 months was 0.97 ± 0.04, and 42.3% of metastatic lymph nodes had completely disappeared. The overall local recurrence rate did not differ significantly between the RFA and RO groups, consistent with the Kaplan-Meier analysis. The RFA group had significantly lower overall complication rates than the RO group (P<0.001), including both nerve-related complications (P = 0.009) and non-nerve-related complications (P = 0.002). Subgroup analysis showed that this safety difference was most evident in Type II lesions. The pre-PSM sensitivity analysis showed a similar trend. In addition, compared with RO, RFA was associated with significantly shorter procedure time, shorter hospital stay, less intraoperative blood loss, and smaller postoperative scar length (all P<0.001). Conclusion: In carefully selected patients with nerve-adjacent R-PTC-SCLNM, RFA demonstrated acceptable short-term local control and a minimally invasive profile characterized by faster recovery and a lower complication burden. RFA may serve as a potential treatment option for patients who are unsuitable for or unwilling to undergo reoperation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.